Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections

June 13, 2023

News, Press Releases

Comments Off on Adaptive Phage Therapeutics Closes on $12 Million Investment in $30 Million Series B1 to Fight Antibiotic Resistant Infections

GAITHERSBURG, MD, June 13, 2023 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, announced today that it has received a $12 million upfront investment from funds managed by Deerfield Management and the AMR Action Fund as part of a new $24 million total investment in […]

Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center

May 24, 2023

Press Releases

Comments Off on Adaptive Phage Therapeutics Enters Collaboration and License Agreement with Hebrew University of Jerusalem and Hadassah Medical Center

GAITHERSBURG, MD, May 24, 2023 – Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, is pleased to announce a collaboration and license agreement with the Israeli Phage Therapy Center (IPTC) of the Hebrew University of Jerusalem and Hadassah Medical Center. Researchers at the IPTC have discovered several phages that […]

Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial

January 24, 2023

News, Press Releases

Comments Off on Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial

Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection GAITHERSBURG, MD, January 12, 2023 – Adaptive Phage Therapeutics, Inc., (APT) a clinical-stage biotechnology company advancing the APT phage bank, the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced the first patient has been dosed in the PHAGE clinical study, an early-stage clinical trial evaluating bacteriophage […]

Adaptive Phage Therapeutics Appoints Edward Fang as Chief Medical Officer

October 25, 2022

News, Press Releases

Comments Off on Adaptive Phage Therapeutics Appoints Edward Fang as Chief Medical Officer

GAITHERSBURG, MD, October 25, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing a phage bank, the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced the appointment of Edward Fang, M.D. as Chief Medical Officer. Dr. Fang’s responsibilities include overseeing clinical development for APT phage bank treatment candidates through […]

Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical Trial

October 4, 2022

News, Press Releases

Comments Off on Adaptive Phage Therapeutics Awarded Additional $5 Million from U.S. Defense Health Agency to Support Diabetic Foot Osteomyelitis Clinical Trial

GAITHERSBURG, MD, October 4, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company advancing the world’s largest therapeutic phage initiative for treatment of bacterial infectious diseases, today announced that the Defense Health Agency (DHA) has awarded an additional $5 million to support clinical development of APT’s adaptive bacteriophage (“phage”) therapy in treatment of diabetic foot […]

Adaptive Phage Therapeutics Announces “The AMR RAPID Challenge” for the Infectious Disease Research Community: Find a Bacteria Resistant to APT’s Investigational Phage Bank

September 7, 2022

News, Press Releases

Comments Off on Adaptive Phage Therapeutics Announces “The AMR RAPID Challenge” for the Infectious Disease Research Community: Find a Bacteria Resistant to APT’s Investigational Phage Bank

GAITHERSBURG, MD, September 7, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company controlling the world’s largest therapeutic phage library initiative and dedicated to providing therapies to treat infectious diseases, today announced “The AMR RAPID™ Challenge” at the World AMR Congress. RAPID is APT’s acronym for Rapidly Adaptive Phage for Infectious Disease. Through this challenge, APT will pay $1,000 to […]

Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis

May 25, 2022

News, Press Releases

Comments Off on Adaptive Phage Therapeutics Announces First Patient Dosed in the DANCE Trial, a Phase 1/2 Study Evaluating APT Phage Bank in Diabetic Foot Osteomyelitis

GAITHERSBURG, MD, May 17, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that the first patient has been dosed in its DFO Adaptive Novel Care Evaluation (DANCE™) trial, a Phase 1/2 clinical study to evaluate the safety and efficacy of APT’s precision bacteriophage (“phage”) therapy in patients with Diabetic Foot Osteomyelitis (DFO). Traditional […]

Adaptive Phage Therapeutics Appoints Rob Casper as Vice President of Clinical Operations

April 26, 2022

Press Releases

Comments Off on Adaptive Phage Therapeutics Appoints Rob Casper as Vice President of Clinical Operations

GAITHERSBURG, MD, April 26, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Rob Casper as Vice President of Clinical Operations. Mr. Casper will oversee execution of global clinical trials of APT’s phage bank therapy. “I am pleased to welcome […]

Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund

April 4, 2022

Press Releases

Comments Off on Adaptive Phage Therapeutics Extends Series B to $61 million with Addition of The AMR Action Fund

–New funding follows initial Series B closing in May 2021– –Funding will be used to accelerate clinical trials against Prosthetic Joint Infection (PJI) and Diabetic Foot Osteomyelitis (DFO) – GAITHERSBURG, MD, April 4, 2022 – Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that […]

Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study

November 2, 2021

Press Releases

Comments Off on Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study

GAITHERSBURG, MD, November 2, 2021 – Adaptive Phage Therapeutics, Inc. (APT), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced that it has entered into an agreement with the Antibacterial Resistance Leadership Group (ARLG) to support a multi-center Phase 1b/2, randomized, double-blind, placebo-controlled trial assessing the safety and microbiological activity of a single […]